<DOC>
	<DOCNO>NCT01832571</DOCNO>
	<brief_summary>This pilot , open-label , prospective study determine feasibility integrate pre-exposure prophylaxis ( PrEP ) exist HIV prevention program female sex worker woman enrol program adhere daily PrEP regimen Truvada® . This study enroll 500 HIV antibody negative female sex worker Eldoret Nairobi , Kenya .</brief_summary>
	<brief_title>SCOPE : Strategies Combine PrEP With Prevention Efforts</brief_title>
	<detailed_description>Participants undergo follow procedure : blood draw HIV ( screen , enrollment , month 1 , quarterly follow-up visit final ) creatinine test ( screen , month 3 final ) urine pregnancy test ( screen , enrollment final ) . At screen , participant HBV antigen test . Information demographic , sexual behavior , risk perception , partner ' HIV status , medical history , PrEP program acceptability , self-reported adherence PrEP , alcohol drug use , depression , social support , stigma , self-efficacy , gender-based violence , contraceptive use , adverse event , symptom potential acute HIV infection collect study . Detailed information Truvada PrEP give participant participant counsel HIV-risk reduction ( accord exist program ) screen visit . Patient-centered integrated counseling HIV risk reduction PrEP adherence conduct enrollment follow-up visit . Sexually transmitted infection ( STI ) assess treated visit per local clinical procedure . If pelvic exam do per routine clinic procedure , vaginal and/or endocervical swab collect stored future research relate HIV infection . A cohort 25 systematically-selected participant site three round in-depth interview ( IDI ) explore context surround many study 's endpoint . The first IDI conduct month 1 visit PrEP initiation . The second IDI conduct month 3 visit . The third IDI conduct final study visit . An IDI conduct participant site assign willing use electronic pill monitor device ( n=25 per site ) . The purpose IDIs explore reason underlie PrEP use pattern ( e.g . number time pill bottle open specific period time -- limited , intermittent , high number opening ) . Two round IDIs conduct participant . The first IDI conduct month 3 visit second month 6 visit . Exit interview conduct 30 participant site . Participants may purposefully select base drug level adherence data electronic pill measurement data ( e.g . low , intermittent , high PrEP user ) base specific issue emerge course study ( e.g. , limited partner support ) . Two brief face-to-face ( FTF ) structure survey administer HIV prevention program staff ass variables/domains related feasibility measure . The first survey administer around initiation study second survey towards end study . Two interview conduct use questionnaire open- closed-ended question , counselor provider , nurse , medical officer , doctor , gather in-depth data feasibility measure . The first interview conduct approximately one month first participant screen second interview toward end study .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>At least 18 year age Willing able ( i.e. , successfully complete openended comprehension assessment key topic relate study ) give write informed consent Expresses willingness screen enrollment take PrEP daily Willing provide contact information contact staff visit ( per participantapproved method ) Is sexually active , define least one vaginal sex act last four week , report receive money good exchange sex last 6 month part source income/livelihood Is HIV antibody negative rapid test algorithm enrollment visit Does symptom suggestive acute HIV infection enrollment visit ( i.e. , fever ( temperature 38ºC ) , fatigue , sweating , night sweat , pain , rash , pharyngitis , headache , muscle joint pain , adenopathy ( cervical inguinal ) , vomit , diarrhea cough ) combine selfreported possibility recent HIV exposure lead clinical suspicion acute HIV infection Has negative urine pregnancy test screening enrollment Is currently try become pregnant Is breastfeeding Has creatinine clearance ≥ 60ml/min ( CockcroftGault formula ) screening Is Hepatitis B virus antigen ( HBV Ag ) negative screening Is general good health medical social condition may make study participation unsafe complicate data interpretation opinion site investigator Is participate another PrEP program PrEP research study Is take HIV postexposure prophylaxis enrollment Pregnant HIV antibody positive Using HIV postexposure prophylaxis enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>PrEP</keyword>
	<keyword>Female Sex Workers</keyword>
	<keyword>Kenya</keyword>
</DOC>